BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a hold rating to a buy rating in a report released on Tuesday.

SGMO has been the subject of several other reports. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 10th. ValuEngine raised shares of Sangamo Therapeutics from a buy rating to a strong-buy rating in a report on Thursday, November 1st. Wedbush reaffirmed a hold rating and issued a $9.00 price objective on shares of Sangamo Therapeutics in a report on Tuesday, July 24th. Guggenheim began coverage on shares of Sangamo Therapeutics in a report on Tuesday, October 9th. They issued a buy rating and a $18.00 price objective for the company. Finally, Cowen reaffirmed a buy rating on shares of Sangamo Therapeutics in a report on Monday, July 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $21.00.

SGMO opened at $11.16 on Tuesday. The company has a market capitalization of $1.41 billion, a P/E ratio of -15.94 and a beta of 3.21. Sangamo Therapeutics has a 12 month low of $11.02 and a 12 month high of $27.50. The company has a quick ratio of 7.24, a current ratio of 7.24 and a debt-to-equity ratio of 0.07.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. The company had revenue of $23.56 million during the quarter, compared to the consensus estimate of $26.96 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same period last year, the firm earned ($0.15) EPS. On average, equities analysts expect that Sangamo Therapeutics will post -0.69 earnings per share for the current year.

In other news, Director H Stewart Parker purchased 2,000 shares of the business’s stock in a transaction on Friday, September 7th. The stock was purchased at an average cost of $13.52 per share, with a total value of $27,040.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $15.39, for a total transaction of $76,950.00. Following the completion of the transaction, the chief financial officer now directly owns 12,250 shares of the company’s stock, valued at $188,527.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,000 shares of company stock valued at $432,350. Insiders own 1.20% of the company’s stock.

A number of large investors have recently made changes to their positions in SGMO. Riverhead Capital Management LLC boosted its holdings in Sangamo Therapeutics by 218.0% in the 2nd quarter. Riverhead Capital Management LLC now owns 8,267 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 5,667 shares during the period. Mount Yale Investment Advisors LLC boosted its holdings in Sangamo Therapeutics by 2,202.8% in the 2nd quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 7,996 shares during the period. NumerixS Investment Technologies Inc bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $125,000. Tyers Asset Management LLC boosted its holdings in Sangamo Therapeutics by 301.3% in the 2nd quarter. Tyers Asset Management LLC now owns 9,632 shares of the biopharmaceutical company’s stock valued at $137,000 after purchasing an additional 7,232 shares during the period. Finally, Quantitative Systematic Strategies LLC bought a new position in Sangamo Therapeutics in the 2nd quarter valued at $155,000. 64.01% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: Find a Trading Strategy That Works

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.